Abstract
Authors: Xiangbing Meng (University of Iowa) , Laura L. Laidler (University of New Mexico) , Lina Albitar (University of New Mexico) , Anna M. Holmes (University of New Mexico) , Donghai Dai (University of Iowa) , Thomas E. Buekers (University of Iowa) , David P. Bender (University of Iowa) , Kimberly K. Leslie (University of Iowa)
Serous uterine endometrial cancer is a lethal disease for which new therapeutic regimens are urgently needed. Combinations of chemotherapeutic agents and small molecule growth factor inhibitors have demonstrated activity in cancers from other sites. Our objective was to determine whether such a combination using Paclitaxel and Gefitinib could be active in serous endometrial cancer cells.
Keywords: Paclitaxel, Gefitinib, endometrial cancer, mitotic catastrophe, p38, p53
How to Cite: Meng, X. , Laidler, L. L. , Albitar, L. , Holmes, A. M. , Dai, D. , Buekers, T. E. , Bender, D. P. & Leslie, K. K. (2011) “The combination of Paclitaxel and Gefitinib inhibits endometrial cancer cells by inducing mitotic catastrophe: proof of principle for dual therapy in endometrial cancer”, Proceedings in Obstetrics and Gynecology. 2(1). doi: https://doi.org/10.17077/2154-4751.1099